Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: GlobeNewswire
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First immunotherapy program to target PIWIL1, a cancer-testis antigen overexpressed in a range of cancers, including colorectal cancer (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 17 December 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that the first patient has been treated in the Phase 1/2 trial of its novel ImmTAC candidate, IMC-R117C, targeting PIWIL1 in colorectal and other gastrointestinal cancers. IMC-R117C is Immunocore’s fifth ImmTAC candidate to enter the clinic. PIWIL1 is overexpressed in multiple malignanci
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development [Yahoo! Finance]Yahoo! Finance
- Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate DevelopmentGlobeNewswire
- 3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 [Yahoo! Finance]Yahoo! Finance
- BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term [Yahoo! Finance]Yahoo! Finance
IMCR
Earnings
- 11/6/24 - Beat
IMCR
Sec Filings
- 1/3/25 - Form 4
- 1/2/25 - Form 8-K
- 11/14/24 - Form SC
- IMCR's page on the SEC website